Biocon

BIOCON

Strengthens Global Biologics Play with Denosumab Breakthrough in Canada💊

Biocon

has received approval from Health Canada for its denosumab biosimilars, Bosaya (reference to Prolia) and Vevzuo (reference to Xgeva). These therapies are key in treating osteoporosis and preventingbone-related complications in cancer patients, marking a strong entry into a high-value biologics segment. Backed by robust clinical data showing no meaningful differences from the originators, this approval strengthens Biocon’s presence in regulated markets and reinforces its strategy of building a global biosimilars portfolio focused on chronic and oncology care.